CN103402582A - 使用抗水肿疗法治疗黄斑水肿的方法 - Google Patents

使用抗水肿疗法治疗黄斑水肿的方法 Download PDF

Info

Publication number
CN103402582A
CN103402582A CN2012800110513A CN201280011051A CN103402582A CN 103402582 A CN103402582 A CN 103402582A CN 2012800110513 A CN2012800110513 A CN 2012800110513A CN 201280011051 A CN201280011051 A CN 201280011051A CN 103402582 A CN103402582 A CN 103402582A
Authority
CN
China
Prior art keywords
letters
months
patient
twenty
vision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800110513A
Other languages
English (en)
Chinese (zh)
Inventor
P·阿什通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Control Delivery Systems Inc
Original Assignee
Control Delivery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Systems Inc filed Critical Control Delivery Systems Inc
Publication of CN103402582A publication Critical patent/CN103402582A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2012800110513A 2011-02-11 2012-02-13 使用抗水肿疗法治疗黄斑水肿的方法 Pending CN103402582A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442151P 2011-02-11 2011-02-11
US61/442,151 2011-02-11
PCT/US2012/024910 WO2012109673A1 (en) 2011-02-11 2012-02-13 Methods of treating macular edema using antiedema therapeutics

Publications (1)

Publication Number Publication Date
CN103402582A true CN103402582A (zh) 2013-11-20

Family

ID=46637026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800110513A Pending CN103402582A (zh) 2011-02-11 2012-02-13 使用抗水肿疗法治疗黄斑水肿的方法

Country Status (8)

Country Link
US (1) US20120207682A1 (https=)
EP (1) EP2673049A4 (https=)
JP (1) JP2014508749A (https=)
CN (1) CN103402582A (https=)
AU (1) AU2012214146A1 (https=)
CA (1) CA2827082A1 (https=)
RU (1) RU2013138180A (https=)
WO (1) WO2012109673A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2968882B1 (en) * 2013-03-12 2021-05-19 EyePoint Pharmaceuticals US, Inc. Drug delivery device comprising silicon-based carrier particles
TR201808197T4 (tr) * 2013-03-14 2018-07-23 Eyecro Llc Mikroemülsiyon topikal dağıtım platformu.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
SG10201809363SA (en) * 2013-11-15 2018-11-29 Allergan Inc Methods of treatment of ocular conditions with a sustained drug delivery implant
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
EP4537830A3 (en) 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ575950A (en) * 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
WO2010129545A2 (en) * 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles

Also Published As

Publication number Publication date
AU2012214146A1 (en) 2013-08-29
RU2013138180A (ru) 2015-03-20
EP2673049A4 (en) 2015-04-08
CA2827082A1 (en) 2012-08-16
US20120207682A1 (en) 2012-08-16
EP2673049A1 (en) 2013-12-18
JP2014508749A (ja) 2014-04-10
WO2012109673A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
CN103402582A (zh) 使用抗水肿疗法治疗黄斑水肿的方法
JP6700348B2 (ja) 持続型薬物送達インプラント
Lee et al. Biodegradable implants for sustained drug release in the eye
Shah et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy
US20230129084A1 (en) Composite implants
AU2006304416B2 (en) Ocular therapy using Glucocorticoid Derivatives selectively penetrating posterior segment tissues
Bansal et al. Posterior segment drug delivery devices: current and novel therapies in development
JP2014508749A5 (https=)
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
CN1972678A (zh) 延长缓释超过2个月的类固醇眼内植入物
KR20060085246A (ko) 경공막 전달
TW200538135A (en) Extended therapeutic effect ocular implant treatments
BR112016010638B1 (pt) Dispositivo ocular
CA2830555A1 (en) Intraocular drug delivery device and associated methods
JP2025507154A (ja) 眼の状態の治療を目的とした連続投薬レジメン
US20160317438A1 (en) Injectable sustained release intraocular device
CN101678034A (zh) 治疗新血管眼病的方法
AU2017388230A1 (en) Intraocular drug delivery device and associated methods
US20240058264A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
Lee et al. Implantable devices to treat ophthalmic conditions: drug delivery systems
Pandya et al. Design and Evaluation of Long Acting Biodegradable PLGA Microspheres for Ocular Drug Delivery
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
Cvenkel et al. Implants to Treat Glaucoma: Promising or Not? B. Cvenkel, M. Kolko
HK40118701A (zh) 用於治疗眼睛病症的持续给药方案
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131120